CLEARSIDE BIOMEDICAL

Clearside Biomedical Expands XIPERE™ License Agreement with Arctic Vision to Include Australia, New Zealand, India and ASEAN Countries

09 Sep 2021 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Present at the Ophthalmology Futures European 2021 Virtual Retina Forum

23 Aug 2021 16:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Second Quarter 2021 Financial Results and Provides Corporate Update

10 Aug 2021 16:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in Two Upcoming Investor Conferences in August 2021

04 Aug 2021 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Report Second Quarter 2021 Financial Results and Provide Corporate Update on Tuesday, August 10, 2021

27 Jul 2021 16:05:02 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

15 Jun 2021 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in Two Upcoming Investor Conferences in June 2021

09 Jun 2021 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces First Quarter 2021 Financial Results and Provides Corporate Update

17 May 2021 16:05:01 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Multiple Poster Presentations at the Association for Research in Vision and Ophthalmology 2021 Virtual Meeting

10 May 2021 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Report First Quarter 2021 Financial Results and Provide Corporate Update on Monday, May 17, 2021

04 May 2021 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Resubmission of New Drug Application for XIPERE™ for Treatment of Macular Edema Associated with Uveitis

03 May 2021 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Present at the Needham Virtual Healthcare Conference and Wet AMD & DME Drug Development Summit

05 Apr 2021 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

10 Mar 2021 16:05:01 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Completion of Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

02 Mar 2021 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update on Wednesday, March 10, 2021

24 Feb 2021 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in Two Upcoming Investor Conferences in March 2021

23 Feb 2021 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces CLS-AX (axitinib injectable suspension) Presentation Delivered at Angiogenesis, Exudation, and Degeneration 2021 Program

16 Feb 2021 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Featured in Multiple Data Presentations at the 44th Virtual Annual Macula Society Meeting

08 Feb 2021 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

12 Jan 2021 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Pricing of $12 Million Registered Direct Offering

06 Jan 2021 07:05:00 By Nasdaq GlobeNewswire